# Robotic-Assisted Lobectomy Following Induction Chemoimmunotherapy Achieves Complete Pathologic Response in Stage IIIA Lung Adenocarcinoma: A Case Report

## TL;DR

A 77-year-old woman with stage IIIA lung cancer achieved complete tumor removal after chemoimmunotherapy and robotic surgery.

## Contribution

This case demonstrates complete pathologic response after chemoimmunotherapy and robotic lobectomy in stage IIIA lung cancer.

## Key findings

- Neoadjuvant chemoimmunotherapy reduced tumor size in a stage IIIA lung cancer patient.
- Robotic lobectomy following therapy resulted in complete pathologic response with no residual tumor.
- Combination therapy and surgery offer potential cure for advanced lung cancer.

## Abstract

Novel therapies for clinical stage IIIA lung cancer are changing the outcomes in advanced clinical stage lung cancer. A 77-year-old female patient diagnosed with clinical T4 or stage IIIA right lower lobe adenocarcinoma with a KRAS mutation. She received neoadjuvant chemoimmunotherapy for an 8 cm tumor, which showed a moderate response on imaging. The patient underwent robotic-assisted thoracoscopic right lower lobectomy and mediastinal lymph node dissection. The final pathology showed a complete response. Novel induction chemoimmunotherapy provides an opportunity to completely eradicate cancer and provides surgical therapy for patients with advanced lung cancer.